Delayed lymphocyte infusion in children given SCT.
The use of DLI can change chimerism and prevent rejection and relapse. However, the prerequisite for a successful use of this powerful and potentially harmful tool is a minimal burden with resting leukemia or in the case of nonmalignant disease autologous cells. Therefore, a monitoring of the hematopoietic chimerism and of the post-transplant MRD is recommended with a narrow (best: weekly) time schedule. Also, using low and increasing numbers of DLI, a GvHD can be avoided or even minimized.
Klingebiel
T
T
Zentrum für Kinder- und Jugendmedizin, Klinik III, Department for Pediatric Hematology and Oncology, Johann Wolfgang Goethe University, Frankfurt/Main, Germany. thomas.klingebiel@kgu.de
Bader
P
P
D002648:Child; D018572:Disease-Free Survival; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D017710:Lymphocyte Transfusion / Q000379:methods*; D033581:Stem Cell Transplantation / Q000379:methods*; D018183:Transplantation Chimera; D014184:Transplantation, Homologous